In contrast to our study, some studies have also reported a lower frequency of HER2-low BC Ki67 ≥ 14% or 20% in HR-negative BC compared to HER2-zero tumours (Ma et al., 2024). This evidence concerns the gene ERBB2 and neoplasm.